OPK

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2002, for eXegenics Inc. (Note: The input metadata lists "OPKO HEALTH, INC.", but the filing text explicitly identifies the registrant as eXegenics Inc.). The company is a post-genomics drug creation enterprise focused on developing therapeutic products for cancer and drug-resistant bacterial diseases. During the period, the company announced a definitive merger agreement with Innovative Drug Delivery Systems, Inc. (IDDS).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped to $0 for the three months ended September 30, 2002, compared to $333,000 in the same period in 2001. For the nine months, revenue decreased to $556,000 from $1,000,000. This is attributed to the completion of all required payments under the Master License Agreement with Bristol-Myers Squibb (BMS).
• Expense Reductions: Research and Development (R&D) expenses decreased by 25% ($282,000) for the quarter and 20% ($811,000) for the nine months compared to the prior year, driven by the discontinuation of non-strategic research projects and reduced contract research costs.
• General and Administrative (G&A): G&A expenses decreased by 10% for the quarter and 17% for the nine months. However, this was partially offset by a $436,000 increase in professional consulting and audit fees related to the pending merger with IDDS.
• Net Loss Improvement: The net loss attributable to common shareholders decreased slightly by 3% for the quarter and 10% for the nine months compared to the prior year periods.

Guidance, Outlook, and Risks

• Merger with IDDS: The company has executed a definitive merger agreement with Innovative Drug Delivery Systems, Inc. (IDDS). If successful, the combined entity will have product candidates ready for Phase III clinical trials. Management assumes cash on hand post-merger will fund operations for at least 12 months.
• Liquidity: As of September 30, 2002, the company held approximately $20.0 million in cash, cash equivalents, and investments. Management believes this is sufficient to finance operations for the next twelve months.
• Revenue Uncertainty: With the cessation of BMS funding, the company has lost its sole source of revenue. There is no assurance of when or if future revenue will be generated.
• Financing Needs: Substantial additional funds will be required for clinical trials and commercialization. The company intends to seek equity, debt, or lease financing, but there is no guarantee such funds will be available on acceptable terms.
• Risk of Merger Failure: If the merger with IDDS is not consummated, the company will have incurred significant non-operating expenses without the benefit of the combined operations, potentially worsening its financial condition.

Investor Verification Checklist

• Merger Status: Verify the current status of the merger agreement with IDDS and the likelihood of shareholder approval.
• Cash Burn Rate: Confirm the projected runway of the $20 million cash balance given the lack of operating revenue.
• Revenue Pipeline: Assess the progress of renegotiating scientific collaborations (e.g., with WSU) and the potential for new licensing deals to replace BMS revenue.
• Merger-Related Costs: Review the specific impact of the $526,000 in merger-related expenses on the current quarter's loss.
• Regulatory Approvals: Monitor the progress of IDDS's Phase III candidates and the regulatory hurdles for the combined company's product pipeline.